Zubairi Maysaa B, Ahmed Jawad H, Al-Haroon Sawsan S
College of Pharmacy, Department of Pharmacology and Toxicology, Basrah College of Medicine, Basrah, Iraq.
Department of Pharmacology, Basrah College of Medicine, Basrah, Iraq.
Indian J Pharmacol. 2014 Nov-Dec;46(6):644-8. doi: 10.4103/0253-7613.144937.
To evaluate hepatoprotective potential of carvedilol, prazosin, metoprolol and prazosin plus metoprolol in paracetamol-induced hepatotoxicity.
Thirty-six male rabbits were divided into six groups, six in each, group 1 received distilled water, group 2 were treated with paracetamol (1 g/kg/day, orally), group 3, 4,5 and 6 were treated at a dose in (mg/kg/day) of the following: Carvedilol (10 mg), prazosin (0.5 mg), metoprolol (10 mg), and a combination of metoprolol (10 mg) and prazosin (0.5 mg) respectively 1 h before paracetamol treatment. All treatments were given for 9 days; animals were sacrificed at day 10. Liver function tests, malondialdehyde (MDA) and glutathione (GSH) in serum and liver homogenates were estimated. Histopathological examinations of liver were performed.
Histopathological changes of hepatotoxicity were found in all paracetamol-treated rabbits. The histopathological findings of paracetamol toxicity disappeared in five rabbits on prazosin, very mild in one. In carvedilol group paracetamol toxicity completely disappeared in three, while mild in three rabbits. Paracetamol hepatotoxicity was not changed by metoprolol. In metoprolol plus prazosin treated rabbits, moderate histopathological changes were observed. Serum liver function tests and MDA in serum and in liver homogenate were elevated; GSH was depleted after paracetamol treatment and returned back to the control value on prior treatment with prazosin. MDA in serum and liver homogenate, alkaline phosphatase, total bilirubin were significantly decreased after carvedilol and prazosin plus metoprolol treatments.
Carvedilol and prazosin are hepatoprotective in paracetamol hepatotoxicity, combination of prazosin and metoprolol have moderate, and metoprolol has a little hepatoprotection.
评估卡维地洛、哌唑嗪、美托洛尔以及哌唑嗪联合美托洛尔对扑热息痛诱导的肝毒性的肝保护潜力。
36只雄性兔子被分为6组,每组6只。第1组给予蒸馏水,第2组用扑热息痛(1克/千克/天,口服)治疗,第3、4、5和6组在扑热息痛治疗前1小时分别用以下剂量(毫克/千克/天)进行治疗:卡维地洛(10毫克)、哌唑嗪(0.5毫克)、美托洛尔(10毫克)以及美托洛尔(10毫克)与哌唑嗪(0.5毫克)的组合。所有治疗均持续9天;在第10天处死动物。评估血清和肝匀浆中的肝功能测试、丙二醛(MDA)和谷胱甘肽(GSH)。对肝脏进行组织病理学检查。
在所有接受扑热息痛治疗的兔子中均发现肝毒性的组织病理学变化。在接受哌唑嗪治疗的5只兔子中,扑热息痛毒性的组织病理学表现消失,1只非常轻微。在卡维地洛组中,3只兔子的扑热息痛毒性完全消失,3只轻微。美托洛尔未改变扑热息痛的肝毒性。在接受美托洛尔加哌唑嗪治疗的兔子中,观察到中度组织病理学变化。血清肝功能测试以及血清和肝匀浆中的MDA升高;扑热息痛治疗后GSH耗竭,在用哌唑嗪预先治疗后恢复到对照值。卡维地洛以及哌唑嗪加美托洛尔治疗后,血清和肝匀浆中的MDA、碱性磷酸酶、总胆红素显著降低。
卡维地洛和哌唑嗪对扑热息痛肝毒性具有肝保护作用,哌唑嗪与美托洛尔的组合具有中度肝保护作用,美托洛尔具有轻微肝保护作用。